


Supplementary Figure S7. Forest plot: Subgroup analysis, factors related to antipsychotic use and dose reduction strategy


D. Actual proportion of reduction

1. Relapse/Hospitalization

1.1 Relapse (primary outcome)




1.2 Hospitalization




2. Study discontinuation


2.1 Study discontinuation due to all causes



2.2 Study discontinuation due to inefficacy




2.3 Study discontinuation due to intolerance




3. Psychopathology


3.1 Total




3.2 Positive symptoms



3.3 Negative symptoms




3.4 CGI-S




4. Adverse effects


4.1 SAS




4.2 BARS




4.3 AIMS




4.4 DIEPSS




4.5 Body weight



4.6 Neurocognition



4.7 QOL




Abbreviations: AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; CGI-S, Clinical Global Impressions – Severity scale; DIEPSS, Drug-Induced Extrapyrimal Symptoms Scale; QOL, quality of life; SAS, Simpson-Angus Scale


E. Duration of reduction

1. Relapse/Hospitalization

1.1 Relapse (primary outcome)




1.2 Hospitalization




2. Study discontinuation


2.1 Study discontinuation due to all causes



2.2 Study discontinuation due to inefficacy




2.3 Study discontinuation due to intolerance




3. Psychopathology


3.1 Total




3.2 Positive symptoms



3.3 Negative symptoms




3.4 CGI-S




4. Adverse effects


4.1 SAS




4.2 BARS




4.3 AIMS




4.4 DIEPSS




4.5 Body weight



4.6 Neurocognition



4.7 QOL




Abbreviations: AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; CGI-S, Clinical Global Impressions – Severity scale; DIEPSS, Drug-Induced Extrapyrimal Symptoms Scale; QOL, quality of life; SAS, Simpson-Angus Scale


F. Speed of reduction

1. Relapse/Hospitalization

1.1 Relapse (primary outcome)




1.2 Hospitalization




2. Study discontinuation


2.1 Study discontinuation due to all causes



2.2 Study discontinuation due to inefficacy




2.3 Study discontinuation due to intolerability




3. Psychopathology


3.1 Total




3.2 Positive symptoms



3.3 Negative symptoms




3.4 CGI-S




4. Adverse effects


4.1 SAS




4.2 BARS




4.3 AIMS




4.4 DIEPSS




4.5 Body weight



4.6 Neurocognition



4.7 QOL



Abbreviations: AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; CGI-S, Clinical Global Impressions – Severity scale; DIEPSS, Drug-Induced Extrapyrimal Symptoms Scale; QOL, quality of life; SAS, Simpson-Angus Scale